CELL INTELLIGENCE · 肿瘤细胞治疗研究

大辩论：CAR-T 细胞疗法对比双特异性抗体治疗 B 细胞淋巴瘤

The Great Debate: CAR-T-Cell Therapy Versus Bispecific Antibodies in B-Cell Lymphoma.

老年套细胞淋巴瘤：生物学风险分层、体能适应性策略与未满足需求

Mantle Cell Lymphoma in Geriatric Patients: Biologic Risk Stratification, Fitness-Adapted Strategies, and Unmet Needs.

短程递增给药 glofitamab 使弥漫大 B 细胞淋巴瘤患者抗 CD19 CAR-T 细胞治疗失败后死亡风险减半：LYSA BiCAR 预设外部对照臂 II 期试验最终结果

Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final result

超越化疗免疫治疗：转化型滤泡性淋巴瘤中新兴的细胞治疗与靶向治疗：范围综述

Beyond Chemoimmunotherapy: Emerging Cellular and Targeted Therapies in Transformed Follicular Lymphoma: A Scoping Review.

Glofitamab 治疗复发/难治性原发性中枢神经系统淋巴瘤的多中心真实世界分析：临床活性、中枢神经系统穿透与 ctDNA 动态

Multicenter Real-World Analysis of Glofitamab in Relapsed/Refractory Primary CNS Lymphoma: Clinical Activity, CNS Penetration, and ctDNA Dynamics.

大 B 细胞淋巴瘤中早期 CD19 CAR-T 细胞治疗失败后挽救治疗的结局

Outcomes of Salvage Therapy after Early-Line CD19 Chimeric Antigen Receptor T-Cell Failure in Large B-Cell Lymphoma.

侵袭性淋巴瘤中的 CAR-T 细胞治疗

Chimeric antigen receptor T-cell therapy in aggressive lymphomas.

成人急性淋巴细胞白血病的治疗：综述

Management of Adult Acute Lymphoblastic Leukemia: A Review.

ALL 的治疗正在迅速变化。研究者已经评估了一线及后线方案，采用酪氨酸激酶抑制剂与免疫治疗的联合方案，化疗强度更低或不再使用化疗。未来研究将评估 CD19、CD20 和 CD22 多靶点抗体及 CAR-T 细胞疗法、新型抗体制剂，以及强度更低/疗程更短的方案。

托珠单抗用于管理 R/R B 细胞 NHL 患者中 T 细胞衔接双特异性抗体相关 CRS 的给药方案

Tocilizumab Dosing for Management of T Cell-Engaging Bispecific Antibody-Related CRS in Patients With R/R B-Cell NHL.

真实世界环境下 Glofitamab 在 R/R DLBCL 患者中的疗效与安全性：一项回顾性研究

Efficacy and safety of Glofitamab in patients with R/R DLBCL in real life setting- a retrospective study.